Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
- Conditions
- Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate CarcinomaStage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage IVA Prostate Cancer AJCC v8
- Interventions
- Registration Number
- NCT04279561
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Brief Summary
This trial studies the effect of androgen receptor signaling inhibitors on 68Ga-PSMA-11 PET/CT imaging in patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). Diagnostic procedures, such as 68Ga-PSMA-11 PET/CT, may help in learning how well androgen receptor signaling inhibitors work in killing castration-resistant prostate cancer cells and allow doctors to plan better treatment.
- Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate short- and long-term prostate specific membrane antigen (PSMA) imaging changes in response to androgen receptor signaling inhibitors (ARSI).
SECONDARY OBJECTIVES:
I. To correlate PSMA imaging changes with prostate specific antigen (PSA) kinetics.
II. To correlate PSMA imaging changes with progression free survival. III. To evaluate the changes in PSMA PET staging (miTNM Prostate Cancer Molecular Imaging Standardized Evaluation \[PROMISE\] criteria) under ARSI.
OUTLINE:
Patients receive gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) intravenously (IV). After 50-100 minutes, patients undergo positron emission tomography (PET)/computed tomography (CT) over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 9
- Histologically proven prostate cancer
- Know metastatic disease on previous imaging, or PSA value ⩾ 1 ng/ml;
- Castration resistant disease with confirmed testosterone level =< 50 ng/ml under prior first-line androgen deprivation therapy (ADT)
- New planned treatment with enzalutamide or abiraterone, darolutamide or apalutamide
- Willingness to undergo ARSI throughout the duration of the study as prescribed by the treating uro-oncologist
- Stated willingness to comply with continuation of ARSI treatment for the duration of the study
- Provision of signed and dated informed consent form
- Inability to provide written informed consent
- Known inability to remain still and lie flat for duration of each imaging procedure (about 30 minutes)
- Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy
- A baseline superscan pattern on bone scan
- Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Diagnostic (68GA-PSMA-11 PET/CT) Gallium Ga 68 Gozetotide Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable). Diagnostic (68GA-PSMA-11 PET/CT) Computed Tomography Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable). Diagnostic (68GA-PSMA-11 PET/CT) Positron Emission Tomography Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).
- Primary Outcome Measures
Name Time Method Changes in 68Ga-PSMA-11 lesion and total-body uptake (standardized uptake value [SUV]max and SUVmean) over time in response to androgen receptor signaling inhibitors (ARSI) Baseline, assessed up to 1 year Changes are expressed in terms of percentage changes from baseline positron emission tomography (PET) (before ARSI). Will utilize mixed effect regression models to evaluate the change over time in PSMA results.
- Secondary Outcome Measures
Name Time Method Prostate specific antigen (PSA) kinetics under ARSI Baseline, assessed up to 1 year Comparison of 68Ga-PSMA-11 uptake (SUVmax and SUVmean) changes over time to PSA kinetics under ARSI. Will use mixed effects regression models to correlate the PSMA and PSA time trends. These models will include the effect of time and the PSMA by time interaction effect.
Biochemical progression free survival (bPFS) Up to 1 year Correlation between 68Ga-PSMA-11 uptake (SUVmax and SUVmean) changes and time of bPFS under ARSI. Will utilize Cox-proportional hazards regression models. PSMA results will be treated as a time dependent covariate in these models.
Changes in lesion size on cross sectional imaging under ARSI Up to 1 year Correlation between SUVmax from 68Ga-PSMA-11 PET and lesion size on cross sectional imaging under ARSI.
Changes in staging (PSMA miTNM PROMISE criteria) under ARSI Up to 1 year Will utilize mixed effects regression models to evaluate the change in staging over time.
Incidence of adverse events Up to 1 year Assessed by Common Terminology Criteria for Adverse Events 4.03.
Trial Locations
- Locations (1)
UCLA / Jonsson Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States